Short answer
Evolent Health, Inc. (EVH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Evolent Health’s financial results for quarter ended September 30, 2026.
Evolent Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Evolent Health’s financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the reported financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $725.4M, up from $479.5M, driven by Performance Suite revenue of $564.3M
- GAAP net loss $23.6M, or $0.21 per share, while adjusted income reached $7.3M, or $0.06 per share
- Adjusted EBITDA $34.3M, margin 4.7%, down from $39.0M and 8.1%, signaling profitability pressure despite strong revenue growth
- Medical expense ratio rose to 93.0% from 85.0%, indicating higher specialty-care costs and potential margin risk
- 2026 revenue guidance reiterated at $2.6B to $2.7B, while Adjusted EBITDA guidance increased to $130.0M to $135.0M
- Seven year-to-date revenue agreements include a four-year surgical renewal and oncology expansions covering approximately 1 million Commercial lives and 11 states
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolent Health, Inc. 8-K filings
Get the next EVH 8-K as it lands
Follow EVH for push alerts, or ask the research agent what this filing means.